betamethasone valerate foam / Generic mfg. - LARVOL DELTA

MROSF: Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial (clinicaltrials.gov) - P1/2 | N=30 | Completed | Sponsor: Ziauddin University | Not yet recruiting ➔ Completed

Trial completion • Fibrosis • Immunology

MROSF: Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Ziauddin University | Initiation date: Mar 2024 ➔ Aug 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial initiation date • Trial primary completion date • Fibrosis • Immunology • TGFB1

A Case of Strongyloides Infection Presenting As Imatinib Sensitivity (EAACI 2024) - "His rash persisted despite stopping imatinib and commencing topical treatment (fexofenadine, cetraben, dermol 500, betnovate). In patients with malignancies a misdiagnosis of the reaction and the subsequent unnecessary treatment cessation can affect prognosis. Moreover, immunosuppressed patients who are at risk of developing strongyloides hyperinfection syndrome, a life threatening complication leading to systemic sepsis and multiorgan failure."

Clinical • Allergy • Immunology

MROSF: Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Ziauddin University

New P1/2 trial • Fibrosis • Immunology • TGFB1

Refractory pyoderma gangrenosum in Caucasian Adolescent with Takayasu arteritis and Life-Threatening Infections (WCD 2023) - "OBSERVATION: This 18-year-old Caucasian man presented with TA at the age 10 and was treated with corticosteroids, methotrexate, anti-TNF therapy (adalimumab), anti-CD20 therapy (rituximab), cyclophosphamide and most latterly tocilizumab and leflunomide...He presented with a six-week history of a left cheek lesion; initially a small, crusted papule that enlarged rapidly, associated with pain, bleeding and purulent discharge not responding to flucloxacillin...Topical immunosuppressive medication (Protopic 0.1% ointment, Betnovate C ointment) was given along with high dose pulsed intravenous methylprednisolone, but the left cheek lesion rapidly enlarged...The acneiform nodules then developed into PG and became superinfected with herpes zoster virus and staph aureus, requiring intravenous acyclovir, antibiotics and hospital admission. Abrocitinib was discontinued and ciclosporin was added with a plan of commencing IV immunoglobulin following several MDT discussions. IVIG was..."

Cardiovascular • Dermatology • Herpes Zoster • Hypertension • Infectious Disease • Pain • Pyoderma Gangrenosum • Varicella Zoster • Vasculitis

A cross-sectional study of dermoscopic features in topical steroid damaged face (WCD 2023) - " Out of 100 patients majority were females(housewives), most common brand used was Betnovate C which contained betamethasone & clioquinol, most common reason for misuse was fairness followed by acne... The present study is conducted to analyze dermoscopic changes in topical steroid damaged/dependent face and correlate with the clinical findings, duration and potency of topical steroid used"

Observational data • Acne Vulgaris • CNS Disorders • Dermatology • Psychiatry

SMART: Skin bioMARkers for Atopic Eczema Therapy Evaluation (clinicaltrials.gov) - P2; N=37; Completed; Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust; Recruiting ➔ Completed; Trial completion date: Apr 2022 ➔ Sep 2021; Trial primary completion date: Jan 2022 ➔ Sep 2021

Biomarker • Clinical • Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • FLG

"नमस्ते भिक मंगे पिक्चर आरही हैं 10rs टिकट लिखना गुनाह हैं सब लिख के रखा हैं शाबास और लूटो Betnovate" (@IAMWORKER5)

Assessment of dermal bioavailability: predicting the input function for topical glucocorticoids using stratum corneum sampling. (PubMed, Drug Deliv Transl Res) - "Betnovate® cream (0.1% w/w BMV) was applied at three doses (2, 5, and 10 mg cm) to the ventral forearms of 12 healthy volunteers...The SC sampling method was able to detect a 50% difference between two applied doses with 80% power; detection of a 20% difference would require a larger sample size. SC sampling enabled quantitative metrics describing corticosteroid delivery to the viable epidermis to be determined."

Journal

Assessing optimal colour and illumination to facilitate reading: an analysis of print size. (PubMed, Ophthalmic Physiol Opt) - "Light source effectiveness and optimal colour/illumination vary as a function of print size. It appears that print size is the most important factor for improving reading speed. As print size decreases, luminance becomes crucial, and only at the smallest print sizes does the effect of colour become useful."

Journal

The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover (clinicaltrials.gov) - P4; N=36; Completed; Sponsor: Jacob Thyssen; Recruiting ➔ Completed; Trial primary completion date: Oct 2020 ➔ Mar 2021

Trial completion • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Assessing optimal colour and illumination to facilitate reading. (PubMed, Ophthalmic Physiol Opt) - "The clinical implications of this study are that reading speeds improve in individuals with low vision under improved lighting conditions, specifically, with higher levels of luminance and colour temperature. The effectiveness of the devices varied across groups; however, the LuxIQ was the only device to improve reading speeds from baseline in older adults with visual impairments."

Journal

SMART: Skin bioMARkers for Atopic Eczema Therapy Evaluation (clinicaltrials.gov) - P2; N=37; Recruiting; Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust; Not yet recruiting ➔ Recruiting; Trial completion date: Apr 2021 ➔ Apr 2022; Initiation date: Mar 2020 ➔ Nov 2020; Trial primary completion date: Apr 2021 ➔ Jan 2022

Biomarker • Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

[VIRTUAL] Systematized delayed‐type hypersensitivity to low‐molecular‐weight heparin in pregnancy: a case report and literature review (BAD 2020) - "She was reviewed by the dermatology team, who recommended fondaparinux SC injections until she gave birth, prior to becoming established on oral apixaban. Her rash resolved completely following treatment with topical betnovate valerate 0.1% and hydromol ointment. She later attended dermatology outpatients for prick testing and intradermal testing to enoxaparin, dalteparin and fondaparinux, as well as patch testing with the standard and medicament series, including samples of enoxaparin and dalteparin...Nadroparin is reported to be the LMWH of highest allergen risk in pregnancy. Our case highlights the significant morbidity that can occur if LMWH allergy is misdiagnosed and confirms the recommended use of fondaparinux as an alternative heparin preparation."

Clinical • Allergy • Atopic Dermatitis • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Ocular Infections • Thrombosis • Venous Thromboembolism

Comparison of Two Lighting Assessment Methods when Reading with Low Vision. (PubMed, Optom Vis Sci) - "Both lighting assessment methods lead to comparable results, but the LuxIQ is easier and faster to use. More research is needed to determine whether the LuxIQ is suitable to be incorporated into clinical practice."

Journal

Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2 (clinicaltrials.gov) - P=N/A; N=50; Recruiting; Sponsor: Nova Southeastern University; N=20 ➔ 50; Trial completion date: Dec 2018 ➔ Jan 2021; Trial primary completion date: Dec 2018 ➔ Dec 2020

Clinical • Enrollment change • Trial completion date • Trial primary completion date

SMART: Skin bioMARkers for Atopic Eczema Therapy Evaluation (clinicaltrials.gov) - P2; N=37; Not yet recruiting; Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Biomarker • Clinical • New P2 trial

The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover (clinicaltrials.gov) - P4; N=36; Recruiting; Sponsor: Jacob Thyssen

New P4 trial

Test-retest Variability of a Standardized Low Vision Lighting Assessment. (PubMed, Optom Vis Sci) - "The measurement of lighting preference lacks the precision necessary for clinical utility, given that the LOA for luminance ranged more than 2600 lux, with normally sighted and low vision participants. Such variability translates into a range of approximately ±40 or 50 W in an incandescent light bulb, depending on the luminance level, making it clinically difficult to narrow down the options for evidence-based lighting recommendations. Next steps are to examine whether the reading behavior of low vision clients is positively affected by interventions that are based on LuxIQ recommendations.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal."

Journal